Dr. Hui Chang has been working for the Sun Yat-sen University Cancer Center since he got his M.D. degree from the Peking Union Medical College in 2011. He has been well trained in radiation therapy and anti-radioresistance research of abdominopelvic (colorectal, urothelial, prostate, etc.) cancers. Up to now, he has published 20 SCI-indexed research papers and leaded 2 provincial scientific research projects.

radioresistance of colorectal, prostate and urothelial cancers; acute toxicities during pelvic irradiation

M.D. (8-year program), Peking Union Medical College, China, 2003 - 2011

1. Chen C, Yi W, …, Chang H#. Serum apolipoprotein B to apolipoprotein A-I ratio is an independent predictor of liver metastasis from locally advanced rectal cancer in patients receiving neoadjuvant chemoradiotherapy plus surgery. BMC Cancer. 2022; 22(1): 7.

2. Guo SP, Chen C, …, Chang H#. Serum Apolipoprotein A-I Predicts Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy. Cancer Manag Res. 2021; 13: 2623-2631.

4. Chang H*, Tao YL, Ye WJ, et al. Regular aspirin intake and prognosis of TxN2-3M0 nasopharyngeal carcinoma: A cohort study based on propensity score matching. Oral Oncol. 2020; 103: 104589. 

5. Chang H*, Chen K, Tao YL, et al. Dosimetric parameters predict radiation-induced choanal stenosis in patients with nasopharyngeal carcinoma. Radiat Oncol. 2020; 15(1): 142.

Updated by International Office, Sun Yat-sen University Cancer Center